Mestinon

Pyridostigmine bromide, the active ingredient in Mestinon, is a cholinesterase inhibitor presented as an oral dosage form for systemic use. It is employed to improve neuromuscular transmission in patients with myasthenia gravis and to alleviate orthostatic hypotension. It is indicated for adult patients and is administered under medical supervision.

GNH USA supplies Mestinon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Mestinon is used to treat conditions that involve impaired cholinergic transmission, primarily within the neuromuscular and autonomic systems.

Myasthenia gravis: enhances neuromuscular transmission, leading to improved muscle strength and reduced fatigue. Orthostatic hypotension: increases vascular tone by augmenting cholinergic activity, helping maintain blood pressure upon standing.

Adverse reactions may occur with pyridostigmine therapy and should be monitored.

Common Side Effects: - Nausea - Diarrhea - Abdominal cramps - Increased salivation - Muscle cramps - Sweating

Serious or Rare Side Effects: - Cholinergic crisis (muscle weakness, respiratory failure) - Severe bradycardia - Bronchospasm - Allergic reactions (rash, angioedema) - Seizures

When prescribing or dispensing Mestinon, consider the following safety measures.

Dose adjustment in renal impairment: reduce dose based on creatinine clearance. Monitor for signs of cholinergic excess: muscle twitching, sweating, gastrointestinal upset. Avoid in patients with known hypersensitivity to pyridostigmine or related compounds. Caution in pregnancy until safety is established: weigh benefits against potential risks. Avoid concomitant use with strong anticholinergic agents: may diminish therapeutic effect. Store at room temperature: keep in the original pack, protect from moisture.

Pyridostigmine bromide may interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Neostigmine: additive cholinergic effects may precipitate crisis. - Beta‑blockers: can exacerbate bradycardia when combined. - Magnesium sulfate: potentiates neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Anticholinergic agents (e.g., atropine): may reduce efficacy of pyridostigmine. - Succinylcholine and other depolarizing anesthetics: increased risk of prolonged paralysis. - Diuretics: may alter electrolyte balance, affecting drug response.